



The 3rd Immunotherapy and Cellular Therapy in Cancer (ICTC) International Summit

March 2-3, 2024 – Online

ictclive.cme-congresses.com

Faculty Disclosures Report

The ICTC Summit seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of the summit meeting participants. In doing so, the ICTC Summit recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The ICTC Summit requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The ICTC Summit considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the ICTC Summit of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the ICTC Summit of CME based on the CME providers of the meeting.

All ICTC Summit Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The ICTC Summit defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

Financial Disclosure Codes

Type of affiliation / financial interest	Code
Honorarium	H
Consultant	C
Other Financial or Material Support	F
Speakers' Bureau	S
Employee	E
Nothing to declare: <i>Written as said statement</i>	
Other: <i>Written as stated on submitted form</i>	

Disclosure Information

Financial interest disclosures from program members and others in a position for control content





The 3rd Immunotherapy and Cellular Therapy in Cancer (ICTC) International Summit

March 2-3, 2024 – Online

ictclive.cme-congresses.com

Summary

Didier Blaise, France

Nothing to declare

Gabriel Brisou, France

C Incyte, Kite/Gilead, BMS, Novartis

F Research funding from BMS

Eolia Brissot, France

C,F Novartis, Astellas, Alexion, Jazz Pharmaceuticals, Kite/Gilead, MSD, Keocyt, Amgen, BMS, Pierre Fabre, Beigene

Antoine Capes, France

Nothing to declare

Bhagirathbhai Dholaria, USA

H Adaptive, ADC, MJH bio, Dava Oncology

C Janssen, Gilead, Acrotech

F Janssen, Pfizer, Gilead, Takeda, Adicet, Wugen, MEI, Angiocrine, Poseida

Rémy Duléry, USA

H Novartis, Takeda

F Ligue Nationale contre le Cancer, Arthur Sachs, Monahan Foundation, Servier Foundation, Philippe Foundation, DCP AP-HP, Kite Pharma/Gilead, Sanofi

Jordan Gauthier, USA

C Sobi, Legend Biotech, Janssen, Kite Pharma, MorphoSys, Century Therapeutics

F Sobi, Juno Therapeutics, Celgene, Angiocrine Bioscience

Yongxian Hu, China

Nothing to declare

He Huang, China

Nothing to declare

Florent Malard, France

H,C Therakos/Mallinckrodt, BMS, MSD, Sanofi, Novartis, Astra Zeneca, Jazz Pharmaceuticals

Mohamad Mohty, France

H Adaptive Biotechnologies, Amgen, Astellas, BMS, GSK, Janssen, Jazz Pharmaceuticals, MaaT, Novartis, Pfizer, Sanofi, Menarini Stemline, Takeda

C Janssen, Jazz Pharmaceuticals, MaaT, Sanofi, Menarini Stemline

F Research funding from Janssen, Jazz Pharmaceuticals, Sanofi
Advisory boards with BMS, GSK, Janssen, Jazz Pharmaceuticals, Pfizer, Sanofi, Menarini Stemline

S Janssen, Jazz Pharmaceuticals, Sanofi

Arnon Nagler, Israel

Nothing to declare

Rizwan Romee, USA

Nothing to declare

Marion Subklewe, Germany

Nothing to declare

Alvaro Urbano-Ispizua, Spain

Nothing to declare

Dongrui Wang, China

Nothing to declare

Yishan Ye, China

Nothing to declare

Jin Zhang, China

F CellOrigin Inc

Mingming Zhang, China

Nothing to declare